Exacerbation of chronic obstructive pulmonary disease: the role and place of antibiotics


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Chronic obstructive pulmonary disease (COPD) is a widespread chronic disease, characterized by recurrent exacerbations, which are the main cause of health-seeking behavior, hospitalization, and deaths. Bacterial pathogens play a key role in the development of COPD exacerbations, which determines the advisability of the use of antimicrobial agents in this clinical situation. Presented article discusses the modern approaches to antibiotic treatment of COPD exacerbations.

Full Text

Restricted Access

About the authors

Anna G. Romanovskikh

Russian Medical Academy of Continuous Professional Education

Email: anngerom@gmail.com
PhD, Associate Professor at the Department of Pulmonology

A. I Sinopalnikov

Russian Medical Academy of Continuous Professional Education

Yu. G Belotserkovskaya

Russian Medical Academy of Continuous Professional Education

I. P Smirnov

Russian Medical Academy of Continuous Professional Education

References

  1. Diaz-Guzman E., Mannino D.M. Epidemiology and prevalence of chronicobstructive pulmonary disease. Clin Chest. Med. 2014;35(1):7-16. doi: 10.1016/j.ccm.2013.10.002.
  2. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (Update 2019). Available from: http:// www.goldcopd.org.
  3. O'Donnell D.E., Parker C.M. COPD exacerbations: Pathophysiol Thorax. 2006;61:354-61.
  4. Donaldson G.C., Seemungal T.A.R., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847-52.
  5. Marchetti N., Criner G.J., Albert R.K. Preventing acute exacerbations and hospital admissions in COPD. Chest. 2013; 143(5):1444-54. doi: 10.1378/chest.12-1801.
  6. Hurst J.R., Vestbo J., Anzueto A., et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl J. Med. 2010;363:1128-38. doi: 10.1056/NEJMoa0909883.
  7. Bafadhel M., McKenna S., Terry S., et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J. Respir Crit Care Med. 2011;184:662-71. doi: 10.1164/rccm.201104-05970C.
  8. Sethi S., Murphy T.F. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl J. Med. 2008;359:2355-65. doi: 10.1056/NEJMra0800353.
  9. Sethi S., Evans N., Grant B. J.B., et al. Acquisition of a new bacterial strain and occurrence of exacerbations of chronic obstructive pulmonary disease. N. Engl J. Med. 2002;347:465-71.
  10. Anthonisen N.R., Manfreda J., Warren C.P., et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987;106:196-204.
  11. Soler N., Agusti C., Angrill J., et al. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax. 2007;62:29-35.
  12. Seneff M.G., Wagner D.P., Wagner R.P., et al. Hospital and 1 -year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA. 1995;975:1852-57.
  13. Siddiqi A., Sethi S. OptJmizing antibiotic selection in treating COPD exacerbations. Int J. Chron Obstruct Pulmon Dis. 2008:3:3;-44.
  14. Vollenweider D.J., Frei A., Steurer-Stey C.A., et al. Antibiotics for exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 20;8:;0:CD0;0257. Doi: ;0.;002/;465;858. CD0W257.pub2.
  15. Llor C., Moragas A., Hemandez S., et al. Efficacy of antibiotic therapy for acute exacerbation of mild to moderate chronic obstructive pulmonary disease. Am J. Respir Crit Care Med. 20;2;;86:7;6-23. Doi: ;0.;;64/rccm.20;206-09960C.
  16. van Velzen P., Ter Riet G., Bresser P., et al. Doxycycline for outpatient-treated acute exacerbation of COPD: a randomized double-blind placebo-controlled trial. Lancet. Respir Med. 2017;5:492-99. Doi: ;0.;0;6/S22;3-2600(;7)30;65-0.
  17. Hassan W.A., Shalan I., Elsobhy M., et al. Impact on antibiotics on acute exacerbation of COPD. Egypt J. Chest Dis Tuberc. 20;5;64:579-85.
  18. Daniels J.M., Snijders D., de Graaff C.S., et al. Antibiotics in addition to systemic corticosteroids for acute exacerbation of chronic obstructive pulmonary disease. Am J. Respir Crit Care Med. 20;0;;8;:;50-7. Doi: ;0.;;64/rccm.200906-08370C.
  19. Wang J.X., Zhang S.M., Li X.M., et al. Acute exacerbations of chronic obstructive pulmonary disease with low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial. Int J. Infect Dis. 2016;48:40-5. Doi: ;0.;0;6/j.ijid.20;6.04.024.
  20. Wilson R., Anzueto A., Miravitlles M., et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J. 20;2:40:;7-27. Doi: ;0.;;83/0903;936.000903;;.
  21. Bafadhel M., McKenna S., Terry S., et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J. Respir Crit Care Med. 20;2;;86:48-55. Doi: ;0.;;64/rccm.20;;08-;5530C.
  22. Rothberg M.B., Pekow P.S., Lahti M., et al. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA. 70;0:303:7035-47. Doi: 10.1001/ jama.20;0.672.
  23. Stefan M.S., Rothberg M.B., Shieh M.S., et al. Association between antibiotic treatment and outcomes in patients hospitalized with acute exacerbations of COPD treated with systemic steroids. Chest. 2013:143:82-90. Doi: 10.1378/ chest.;2-0649.
  24. Torumkuney D., Mayanskiy N., Edelstein M., et al. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Russia. J. Antimicrob Chemother. 20;8;73(5):;4-2;. Doi: 10.1093/ jac/dky065.
  25. Козлов Р.С., Сухорукова М.В., Сивая О.В. и др. Чувствительность к антимикробным препаратам клинических штаммов Streptococcus pneumoniae, выделенных в различных регионах РФ в 2010-20;3 гг Клиническая микробиология и антимикробная химиотерапия. 20;5;;7(Прил. 1):31.
  26. Sivaya O., Kozlov R., Sukhorukova M., et al. Longterm surveillance of antimicrobial resistance of H. influenzae in Russia: are there any changes in ten years? ECCMID. 20;6;EV0302.
  27. Siempos I.I., Dimopoulos G., Korbila I.P., et al. Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchtis: a meta-analysis. Eur Respir J. 2007:29:;;27-37.
  28. Pettigrew M.M., Tsuji B.T., Gent J.F., et al. Effect of fluoroquinolones and macrolides on eradication and resistance of Haemophilus influenzae in chronic obstructive pulmonary disease. Antimicrob Agents Chemother. 2016;60(7):4151-58. doi: 10.1128/AAC.00301-16.
  29. Desai H., Richter S., Doern G., et al. Antibiotic resistance in sputum isolates of Streptococcus pneumonia in chronic obstructive pulmonary disease is related to antibiotic exposure. COPD. 2010;7:337-44. doi: 10.3109/15412555.2010.510162.
  30. Dimopoulos G., Siempos I.I., Korbila I.P., et al. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: a meta-analysis randomized controlled trials. Chest. 2007;132:447-55.
  31. Bartlett J.G., Sethi S. Management of infection in exacerbation chronic obstructive pulmonary disease. http://www.uptodate.com.
  32. Woodhead M., Blasi F., Ewig S., et al. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect. 2011;17(6):1-
  33. doi: 10.1111/j.1469-0691.2011.03672.x.
  34. Чучалин А.Г., Айсанов З.Р., Авдеев С.Н. и др. Клинические рекомендации: Хроническая обструктивная болезнь легких. 2018. URL: http://cr.rosminzdrav.ru

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies